Thursday, December 11, 2025
  • English
  • Marathi
No Result
View All Result
Daily PRABHAT
  • Home
  • Latest News
  • National
  • International
  • Entertainment
  • Politics
  • Sports
  • Business
  • More
    • Health
    • Lifestyle
    • Technology
    • Science
Daily PRABHAT
No Result
View All Result
  • Home
  • Latest News
  • National
  • International
  • Entertainment
  • Politics
  • Sports
  • Business
  • More
Home Headlines

Mansukh Mandaviya’s important information regarding approval to Covaxin

by Digital Desk
4 years ago
in Headlines, National, Top News
A A
Bharat Biotech awaits feedback from WHO for Covaxin’s emergency use listing
Share on FacebookShare on Twitter

New Delhi – Union Health Minister Mansukh Mandaviya on Tuesday said that approval for Hyderabad-based Bharat Biotech’s COVID-19 vaccine Covaxin will be given on the basis of the meeting which will be convened by the World Health Organization (WHO) today.

“WHO has a system in which there is a technical committee which has approved it (Covaxin) while the other committee is meeting today. The approval for Covaxin will be given on the basis of today’s meeting,” said Union Health Minister during a press briefing here.

Earlier this month, WHO chief scientist Dr Soumya Swaminathan had said that WHO’s technical advisory group will meet on October 26 to consider emergency use listing (EUL) for Covaxin.

The WHO last week had said a vaccine recommended by it for emergency use must be evaluated thoroughly.

“We are aware that many people are waiting for WHO’s recommendation for Covaxin to be included in the COVID19 Emergency Use Listing, but we cannot cut corners – before recommending a product for emergency use, we must evaluate it thoroughly to make sure it is safe and effective,” the organisation had said.

The WHO had said that the timeframe for the WHO Emergency Use Listing procedure depends on how quickly a company producing the vaccine is able to provide the required data.

“The timeframe for the WHO Emergency Use Listing procedure is dependent on how quickly a company producing the vaccine is able to provide the data required for WHO to evaluate the vaccine’s quality, safety, efficacy and its suitability for low- and middle-income countries,” it said.

Bharat Biotech has been submitting data to WHO on a rolling basis and submitted additional information at WHO’s request on September 27.

Covaxin, India’s first indigenous COVID-19 vaccine, has been developed by Hyderabad-based Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).

Tags: coronacorona updatenational
ShareTweetSendShareSend

Latest News

Maharashtra: Massive fire at factory in MIDC brought under control in Jalgaon, no casualties reported

US Representative Bill Huizenga terms India ties “a defining relationship of the 21st century”

“India is one of the fastest-growing major economies”: US Representative Bill Huizenga

Inclusion of Deepavali in UNESCO’s intangible cultural heritage list is matter of pride: UP CM Yogi

Delhi Police bust illegal unit making fake Castrol products in Alipur

Trump says he delivered “pretty strong words” on Ukraine in call with European leaders

Trump questions Ukraine’s election timeline, tells Zelenskyy to be “realistic”

Election Commission extends final publication of revised electoral rolls in West Bengal

BJP welcomes renaming Himachal Raj Bhavan to Lok Bhavan; calls it “historic step in strengthening democracy”

Daily average train services rise to 11,740 post-Covid-19 rationalisation from pre-pandemic level of 11,283 daily trains

New Delhi - Union Health Minister Mansukh Mandaviya on Tuesday said that approval for Hyderabad-based Bharat Biotech's COVID-19 vaccine Covaxin will be given on the basis of the meeting which will be convened by the World Health Organization (WHO) today. "WHO has a system in which there is a technical committee which has approved it (Covaxin) while the other committee is meeting today. The approval for Covaxin will be given on the basis of today's meeting," said Union Health Minister during a press briefing here. Earlier this month, WHO chief scientist Dr Soumya Swaminathan had said that WHO's technical advisory group will meet on October 26 to consider emergency use listing (EUL) for Covaxin. The WHO last week had said a vaccine recommended by it for emergency use must be evaluated thoroughly. "We are aware that many people are waiting for WHO's recommendation for Covaxin to be included in the COVID19 Emergency Use Listing, but we cannot cut corners - before recommending a product for emergency use, we must evaluate it thoroughly to make sure it is safe and effective," the organisation had said. The WHO had said that the timeframe for the WHO Emergency Use Listing procedure depends on how quickly a company producing the vaccine is able to provide the required data. "The timeframe for the WHO Emergency Use Listing procedure is dependent on how quickly a company producing the vaccine is able to provide the data required for WHO to evaluate the vaccine's quality, safety, efficacy and its suitability for low- and middle-income countries," it said. Bharat Biotech has been submitting data to WHO on a rolling basis and submitted additional information at WHO's request on September 27. Covaxin, India's first indigenous COVID-19 vaccine, has been developed by Hyderabad-based Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
No Result
View All Result
  • Home
  • Latest News
  • National
  • International
  • Entertainment
  • Politics
  • Sports
  • Business
  • More
    • Health
    • Lifestyle
    • Technology
    • Science